DNA Gut tests and reports on evidence-based, clinically useful, human genetic variants that predispose individuals to alterations in gut homeostasis. These alterations are known to have negative consequences for human health. The report offers personalised diet, lifestyle and nutraceutical interventions to support relevant pathways and help you achieve and maintain a healthy and resilient gastrointestinal tract.
The test is suitable for those suffering from, or predisposed to, IBS, IBD, coeliac disease, gut dysbiosis, non-coeliac gluten sensitivity or lactose intolerance, food sensitivities, chronic bloating, diarrhoea, or constipation, autoimmune tendencies and recurrent infections, as well as mental health conditions linked to gut health including mood, cognition, and neurodegenerative conditions. It should also be considered in anyone seeking preventative, root-cause care.

The DNA Gut report organises results into a concise summary of prioritised pathways that impact the  Five DNA Gut Health Pillars - Motility, Presence of Pathobionts, Aberrant Microbial Metabolite Production, Gut Barrier Integrity, Immune Function - providing a lifetime genetic blueprint of gut health predispositions presented as colour-coded areas of potential risk.
The Clear explanations and visuals for each gene variant and pathway, coupled by targeted recommendations for diet, supplements, probiotics, and lifestyle and prompts for further testing (GI-MAP, Zonulin, Gluten Peptide, Stool OMX, SIBO, Toxin Panels etc.) enables practitioners to prioritise key areas with coordinated, targeted and effective treatment strategies.


There is significant evidence highlighting the link between how the Gut Microbiota impacts our genes. Gut bacteria produce a vast array of compounds (microbial metabolites) which act as messengers, these metabolites can directly or indirectly influence our gene expression by altering DNA methylation. Microbes also influence the expression of genes involved in immune responses and the expression of genes related to lipid metabolism, glucose regulation, and nutrient absorption.
On the other hand, the human genome plays a major role in our gut health by 1. Shaping our gut environment through immune system genes that regulate which bacteria can colonize the gut, encoding proteins that create our gut lining and its protective mucus layer, and encoding digestive enzymes responsible for breaking down food. And 2. Influencing nutrient availability by determining how our bodies process and absorb nutrients and what substrates and cofactors are available to important gut enzymes and gut microbiota.
Knowledge of genetic risk variants together with functional testing enables better understanding of the patient’s symptom set and allows for deep insights into the driving factors leading to disease development.

Tests for:
Genotype impact on gut-related conditions.
Analytes measured:
The Panel includes 26 variants across 18 genes



DNA Gut provides valuable insight into the genetic contribution of key biological pathways that influence gut health and allows for a deeper understanding of individual responsiveness to the environment for a healthier gut.
Altered functioning of key biological pathways may weaken one of the five DNA Gut pillars, increasing risk for dysbiosis and predisposition for gut-related health disorders.
Gut transit time and motility
Presence of pathobionts
Aberrant microbial metabolite production
Compromised gut barrier integrity
Altered immune function

Test type:

DNA: Gene

The test is suitable for those who are suffering from, have a family history of, or are inclined to, IBS, IBD, coeliac disease, gut dysbiosis, non-coeliac gluten sensitivity or lactose intolerance, food sensitivities, chronic bloating, diarrhoea, or constipation, autoimmune tendencies and recurrent infections, as well as mental health conditions linked to gut health including mood, cognition, and neurodegenerative conditions. It should also be considered in anyone seeking preventative, root-cause care.


Sample required:

Blood Spot

Average processing time:

18-21 days

Research
Hou M, Xu G, Ran M, Luo W, Wang H. APOE-e4 Carrier Status and Gut Microbiota Dysbiosis in Patients With Alzheimer Disease. Front Neurosci. 2021;15:619051.
Wacklin P, Mäkivuokko H, Alakulppi N, Nikkilä J, Tenkanen H, Räbinä J, et al. Secretor Genotype (FUT2 gene) Is Strongly Associated with the Composition of Bifidobacteria in the Human Intestine. PLoS ONE. 2011 May 19;6(5):e20113.
Mogensen TH. Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses. Clin Microbiol Rev. 2009 Apr;22(2):240–73.
Hold GL, Berry S, Saunders KA, Drew J, Mayer C, Brookes H, et al. The TLR4 D299G and T399I SNPs Are Constitutively Active to Up-Regulate Expression of Trif-Dependent Genes. PLoS ONE. 2014 Nov 3;9(11):e111460.
Salem M, Ammitzboell M, Nys K, Seidelin JB, Nielsen OH. ATG16L1: A multifunctional susceptibility factor in Crohn disease. Autophagy. 2015 Apr 23;11(4):585.
Jauregi-Miguel A, Santin I, Garcia-Etxebarria K, Olazagoitia-Garmendia A, Romero-Garmendia I, Sebastian-delaCruz M, et al. MAGI2 Gene Region and Celiac Disease. Front Nutr. 2019 Dec 19;6:187.
Kafentzi T, Tsounis EP, Tourkochristou E, Avramopoulou E, Aggeletopoulou I, Geramoutsos G, et al. Genetic Polymorphisms (ApaI, FokI, BsmI, and TaqI) of the Vitamin D Receptor (VDR) Influence the Natural History and Phenotype of Crohn’s Disease. Int J Mol Sci. 2025 Jan;26(5):1848.
Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of FokI Variants. J Bone Miner Res. 1998;13(11):1691–9.
Paz JLP, Silvestre M do PSCA, Moura LS, Furlaneto IP, Rodrigues YC, Lima KVB, et al. Association of the polymorphism of the vitamin D receptor gene (VDR) with the risk of leprosy in the Brazilian Amazon. Biosci Rep. 2021 Jul 6;41(7):BSR20204102.
Su Y, Zhao H. Predisposition of Inflammatory Bowel Disease Is Influenced by IL-8, IL-10, and IL-18 Polymorphisms: A Meta-Analysis. Int Arch Allergy Immunol. 2020;181(10):799–806.
Zhu SW, Liu ZJ, Sun QH, Duan LP. Effect of the interleukin 10 polymorphisms on interleukin 10 production and visceral hypersensitivity in Chinese patients with diarrhea-predominant irritable bowel syndrome. Chin Med J (Engl). 2019 Jul 5;132(13):1524.
Meglio PD, Cesare AD, Laggner U, Chu CC, Napolitano L, Villanova F, et al. The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans. PLOS ONE. 2011 Feb 22;6(2):e17160.
Perše M, Unkovic A, Perše M, Unkovic A. The Role of TNF in the Pathogenesis of Inflammatory Bowel Disease. In: Biological Therapy for Inflammatory Bowel Disease [Internet].
Zhao T, Zhang Y, Lee J, Starkweather AR, Young EE, Cong X. The Associations of Single Nucleotide Polymorphisms with Risk and Symptoms of Irritable Bowel Syndrome. J Pers Med. 2022 Jan 21;12(2):142.
Eam F, et al. SLC39A8 missense variant is associated with Crohn’s disease but does not have a major impact on gut microbiome composition in healthy subjects. PloS One [Internet]. 2019 Jan 31 [cited 2025 Feb 20];14(1). Available from: https://pubmed.ncbi.nlm.nih.gov/30703110/.
Pereira C, Grácio D, Teixeira JP, Magro F. Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015 Oct;21(10):2403–17.
Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, et al. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet. 2008 Oct 1;17(19):2967–77.
Gujral N. Celiac disease: Prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol. 2012;18(42):6036.
Gromova LV, Fetissov SO, Gruzdkov AA. Mechanisms of Glucose Absorption in the Small Intestine in Health and Metabolic Diseases and Their Role in Appetite Regulation. Nutrients. 2021 Jul 20;13(7):2474.
Porzi M, Burton-Pimentel KJ, Walther B, Vergères G. Development of Personalized Nutrition: Applications in Lactose Intolerance Diagnosis and Management. Nutrients. 2021 Apr 29;13(5).